The phase 3 CRYSTAL trial investigated the efficacy of combining lesinurad (200 mg or 400 mg), a selective urate transporter inhibitor, with febuxostat treatment for tophaceous gout. The proportion of patients achieving serum urate levels <5.0 mg/dl at 6 months (the primary end point) was higher among patients receiving 400 mg lesinurad in addition to 80 mg febuxostat than among patients receiving febuxostat alone. At all other time points (up to 12 months), 200 mg lesinurad plus febuxostat was more effective than 400 mg lesinurad plus febuxostat in achieving the target levels of serum urate.
References
Dalbeth, N. et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: a phase III clinical trial. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.40159 (2017)
Rights and permissions
About this article
Cite this article
Ummarino, D. Combination therapy effective in tophaceous gout. Nat Rev Rheumatol 13, 450 (2017). https://doi.org/10.1038/nrrheum.2017.112
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.112